Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

Cyclophosphamide 57fludarabine phosphate 48Tacrolimus 39Peripheral Blood Stem Cell Transplantation 37Busulfan 36Mycophenolic Acid 34Whole-Body Irradiation 31Antilymphocyte Serum 28Methotrexate 26Cyclosporine 25fludarabine 23Melphalan 18Filgrastim 15Radiotherapy 14thymoglobulin 12ruxolitinib 12Methylprednisolone 12Cord Blood Stem Cell Transplantation 12Stem Cell Transplantation 11Sirolimus 11Psychiatric Rehabilitation 9Flow Cytometry 9Etoposide 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7merphos 6Therapeutics 6Decitabine 6Cyclosporins 6Azacitidine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Myelofibrosis × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡